<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278079</url>
  </required_header>
  <id_info>
    <org_study_id>TUORU001</org_study_id>
    <nct_id>NCT04278079</nct_id>
  </id_info>
  <brief_title>Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy</brief_title>
  <official_title>Evaluation of Pars Plana Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the effectiveness and safety of pars plans vitrectomy, with internal limiting
      membrane peeling for cases of myopic traction maculopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Performing pars plana vitrectomy for highly myopic patients with decreased visual acuity is
      the standard of care for patients with myopic traction. A variety of findings are seen by
      Optical Coherence Tomography. Epiretinal membranes, retinoschisis, lamellar macular holes,
      and full thickness macular holes are seen. Undergoing vitrectomy, with or without tamponade,
      in our center, is retrospectively evaluated. Visual acuity change, as well as improvement of
      the retinal structure by OCT will be examined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Myopic Traction Maculopathy</condition>
  <condition>Pars Plana Vitrectomy</condition>
  <condition>Internal Limiting Membrane Peeling</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars Plana Vitrectomy with Internal Limiting Membrane peel</intervention_name>
    <description>Pars plana vitrectomy with staining and peeling of internal limiting membrane</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Highly myopic patients, having a refractive errors (spherical equivalent) of more than
             - 8 Diopter, or an axial length more than 26.5 mm.

          -  Best Corrected Visual Acuity less than 0.1

          -  Spectral Domain Optical Coherence Tomography showed; staphylomatous changes, with
             either: Macular retinoschisis, foveal retinal detachment, full thickness macular hole
             (with or without macualr hole retinal detachment), or lamellar macular hole, with
             epiretinal membrane

        At least 6 months follow-up

        Exclusion Criteria:

          -  Eyes with diffuse chorioretinal macular atrophy

          -  Concomitant presence of a choroidal neovascular membrane

          -  Young patients less than 21 years old.

          -  History of trauma

          -  Dense media opacity (corneal/ lenticular)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sharif Yousef El Emam</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

